Food allergy ingredients do NOT have to be listed on vaccines!
Inactive ingredients, such as peanut oil in an adjuvant or vaccine carrier, does not have to appear on the label of a vaccine.
Date: 1/18/2009 3:26:19 PM ( 15 y ) ... viewed 4997 times
The biggest objection I have come across to my hypothesis
which is now "Vaccines are the major cause of food allergy" is that we have
laws so the vaccine manufacturers have to list all of the ingredients on the
package insert.
Ding, dong,
you're wrong!!
Food has to
be labeled. Medicines are not food. Active ingredients appear on the labels
- "inactive" ingredients don't have to....
|
http://www.vran.org/vaccines/anaphylaxis/vaccine-ana.htm
What is being injected into our children? Why can't we find
out? What adjuvants are used in the vaccines?
An Access to Information request to Health Canada for the
100% composition of vaccines given to infants received the response, "I
regret to inform you that the exact composition of these vaccines cannot be
disclosed to you as the information is protected under ATIA (Access to
Information Act) Section 20(1)(a)(b)(c). This is a mandatory exemption which
protects confidential business information."
The Act, under Third Party Information, states, 20. (1) Subject to this section,
the head of a government institution shall refuse to disclose any record
requested under this Act that contains a) trade secrets of a third party; b)
financial, commercial, scientific or technical information that is confidential
information supplied to a government institution by a third party and is treated
consistently in a confidential manner by the third party; c) information the
disclosure of which could reasonably be expected to result in material financial
loss or gain to, or could reasonably be expected to prejudice the competitive
position of, a third party; or d) information the disclosure of which could
reasonably be expected to interfere with contractual or other negotiations of a
third party."
|
http://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_51.pdf
VETERINARY
SERVICES MEMORANDUM NO. 800.51
It is understood
that in some cases, adjuvants are purchased from another firm and therefore
some of the data listed may be the
proprietary information of the supplier and may not be
available to an applicant buying the materials from that source. In this
case, it is acceptable for the applicant to arrange to have the adjuvant
supplier submit adjuvant information to the CVB, in a manner that
protects confidential business
information.
|
http://www.techagreements.com/agreement-preview.aspx?num=616974&title=Avant%20Immunotherapeutics%20-%20Collaboration%20And%20License%20Agreement
VLP.
Drug delivery vehicles, adjuvants,
and excipients shall not be deemed to be "active ingredients",
except in the case where such delivery vehicle, adjuvant, or excipient is
recognized as an active ingredient in accordance with 21 C.F.R. 210.3(b)(7). |
http://www.123jump.com/10K_Reports/ANDS/2005/2005.htm
Intellectual Property and Patents
Our policy is to pursue patents and to otherwise endeavor to
protect our technology, inventions and improvements that are commercially
important to the development of our business. We also rely upon trade
secrets that may be important to the development of our business.
Our success will depend in large part on our ability to:
|
|
• |
obtain and maintain patent
and other proprietary protection for the technology, inventions and
improvements we consider important to our business; |
|
|
|
• |
defend our patents; |
|
|
|
• |
preserve the
confidentiality of our trade secrets; and |
...We
also rely on trade secrets to protect our technology, especially
where we do not believe patent protection is appropriate or obtainable. |
http://www.patentstorm.us/patents/6398774/description.html
Exhibit D, Trade
Secret/Confidential Information--(enclosed separately) |
http://query.nytimes.com/gst/fullpage.html?sec=health&res=9a00e2d8153ff934a15754c0a9609c8b63
The nature of
GlaxoSmithKline's adjuvant is a trade
secret, but David Stout, president for worldwide pharmaceuticals at
the company, said the ingredients had already been given to people in other
products, though not in this particular combination. |
from A Shot
in the Dark By Harris L.
Coulter, Barbara Loe Fisher
"Today, the whole-cell vaccine is made in essentially the
same way as in the time of Bordet and Gengou, although each manufacturer
prepares it differently, and the
exact formula is considered a trade secret." |
http://www.henkebartram.com/articles/Qualifying-for-Trade-Secret-Protection.pdf
Qualifying for Trade Secret
Protection
The case of
Merck & Co., Inc. v. Smithkline Beecham Pharmaceuticals gives an
example. The plaintiff claimed trade secret protection for a process it
developed for the production of a vaccine. The defendant claimed that the
process was not a trade secret because its aspects were readily
ascertainable in publications. The court rejected the defendant’s argument,
stating that “[T]he choice of individually known components and techniques
to create a working manufacturing process is often, as here, a difficult
undertaking. Where at individual
steps of a process there are a variety of alternatives, the choice made
through much effort of specific ingredients, materials, conditions and steps
in an actual, working process constitutes a trade secret.”
|
http://www.ehponline.org/docs/2008/116-10/EHP116pa418PDF.PDF
Because the
actual levels of thimerosal used in
each vaccine are a trade secret, we were not able to directly
control for possible exposure to thimerosal in our analysis.
|
http://www.ibiblio.org/pub/archives/whitehouse-papers/1993/Apr/Immunization-Fact-Sheet-4193
Universal
Vaccine Purchase and Provision
The bill would require that the Secretary consult with other Federal
agencies for advice on the quantities of recommended childhood vaccine to be
purchased. It would authorize the Secretary to consult with
representatives of State governments, experts in vaccine delivery, health
care providers, and other experts prior to commencing negotiations for the
purchase of vaccine.
This proposal would direct the Secretary to negotiate a reasonable price
with manufacturers participating in a procurement. The price would be
based on data supplied to the Secretary by manufacturers regarding (1) costs
related to research and development, production, distribution to States and
health care providers, and marketing; (2) profit levels sufficient to
encourage future investment in research and development; and (3) the ability
to maintain adequate outbreak control. In addition,
the bill would require that data provided to the Secretary be treated as a
trade secret or confidential
information for purposes of the Freedom of Information Act and would provide
criminal sanctions for violations of this provision.
|
http://www.leg.state.fl.us/data/session/2005/Senate/bills/billtext/pdf/s2034.pdf
A bill to be entitled
2 An act relating to public records
exemptions;
3 creating s. 288.961, F.S.; clarifying
the
4 public records exemption relating to
trade
5
secrets for proprietary confidential
business
6 information owned or controlled by
the
7 not-for-profit corporation operating
the
8 Florida Vaccine Research Institute
and its
9 subsidiaries; expanding the public
records
10 exemption to include information
received from
11 a person in this or another state or
nation or
12 the Federal Government which is
otherwise
13 exempt or confidential under the
laws of this
14 or another state or nation or under
federal
15 law; providing for future review and
repeal;
16 providing a statement of public
necessity;
17 providing an effective date.
|
http://www.ahrp.org/cgi-bin/perlfect/search/search.pl?q=infomails
8.
Was Traci Johnson driven
to suicide by anti-depressants? That's a
trade secret, ...
Was Traci Johnson driven to suicide by
anti-depressants? That's a
trade
secret, say US officials Search Archives Preview New Site About AHRP /
Mission Statement What's...
URL: http://www.ahrp.org/infomail/05/06/19.php
Score: 18% Date: - Size:
19 kB |
http://www.lex-electronica.org/docs/articles_71.pdf
Intellectual
Property Protection for Plant Derived Vaccine Technology:
Here They Come Are we Ready or
Not?
Presently the most common source of IP protection sought for PDVs is a
patent. PDVs may also be protected as trade secrets. Trade secret protection
is not grounded in statute, but is rooted in business practices which
protect confidentiality of information relating to an innovation.8 Trade
secret protection relies upon confidentiality rather than registration and
is understood to be an alternative to patent protection.9 Reliance upon
confidentiality renders trade secret a fragile IP right, because the
protection can be immediately and irretrievably lost upon disclosure.
Nowadays, due to innovations which promote quick and wide-spread
distribution of information, such as the internet, trade secret protection
can literally be lost at the push of a button.
The upside of trade secret
protection is the competitive advantage that it can provide because, unlike
patents, no public disclosure is required. In an
environment where adequate confidentiality measures are in place and
enforceable, trade secrets provide an effective means of concealing
information from the public and thereby securing a market sector monopoly.10
|
http://www.uscfc.uscourts.gov/book/export/html/4044
(1) that is
trade secret or commercial or
financial in substance and is privileged or confidential; or |
https://www.softwaretechnews.com/stn_view.php?stn_id=45&article_id=109
Introduction to U.S. Intellectual Property
Law
by Robert L. Vienneau, ITT Corporation and
Milton Johns, ITT Corporation
Trade secrets
are defined in a slightly different way in each state, but the Uniform Trade
Secrets Act, as amended in 1980 (hereafter “UTSA”), is a good point of
departure for a general definition. Under the UTSA,
“ ‘Trade secret’ means information, including a formula,
pattern, compilation, program, device, method, technique, or process, that (i)
derives independent economic value, actual or potential, from not being
generally known to, and not being readily ascertainable by proper means by,
other persons who can obtain economic value from its disclosure or use, and
(ii) is the subject of efforts that are reasonable under the circumstances
to maintain its secrecy.”
|
http://www.vran.org/vaccines/vacing/vac-ing-can.htm
People should
also know that
the manufacturers do not disclose all the ingredients nor
full details of the manufacturing process.
Health Canada protects the
"proprietary rights" of these companies and upholds their right to secrecy -
something the greater Canadian public should be up in arms about. That
parents are expected to submit their children for injection with multiple
vaccines without first having full disclosure of all known ingredients is a
disturbing statement on the control exerted by monopoly medicine and
corporate and government allies. |
http://www.udaan.org/autism/vaccine_safety.html
Strangely vaccine damaged children also have high levels of
arsenic and lead in their bodies. Are these also a component of vaccines?
Unless a full disclosure is
made it is difficult to say what exactly vaccines are composed of. |
http://www.khlaw.com/showpublication.aspx?Show=608
Labeling of GMO-Derived
Food Ingredients: A Recipe for Misinformation
The consumer’s
need for accurate information is of paramount importance: no one here
disputes this fact. What we all should remember, however, is that this need
is not a mandate for selective inclusion of label information by individuals
or groups that may support or oppose a given technology or ingredient. There
is, rather, an ethical and moral imperative to provide
full, accurate and
non-misleading information that is of real value to consumers. The consumer
has no right to misleading information and does not wish to be misled. A
simple statement regarding the presence of genetically modified components,
delivered out of context and without appropriate elaboration, fails this
test entirely. Inaccurate and misleading information is worse than no
information at all. For this reason this Committee should, indeed must,
oppose any further efforts to mandate, endorse or agree to uninformative,
inaccurate and incomplete labeling cloaked in the guise of
full disclosure, until such
time as it can establish meaningful criteria to ensure that consumers
receive the whole story, and not just what one or another interested party
would like them to know.
|
A northern state
in Nigeria that is at the heart of a spreading polio outbreak said Sunday
that it would not relent on its boycott of a mass vaccination program, which
it has called a U.S. plot to spread AIDS and infertility among Muslims ....Kano
state officials say their lab tests carried out late last year found
estrogen and other female sex hormones in the polio vaccine -- proof, they
say, that the vaccines are contaminated.
[Media Feb 2004]
Province at heart of outbreak alleges anti-Muslim plot
The Associated
Press obtained a copy of the committee's interim report that ruled the
vaccines safe. However, it acknowledged the tests showed
"trace
amounts of estradiol," a form of the female hormone estrogen the vaccine's
Muslim detractors claim could cause infertility. ...Muslims in Nigeria's
north have been wary of vaccine campaigns since 1996, when families in Kano
state accused New York-based Pfizer Inc. of using an experimental meningitis
drug without fully informing of the risks.....The company
denied any wrongdoing. A U.S. court dismissed a lawsuit by 20 disabled
Nigerians who allegedly took part in the study, but a U.S. appeals court
later revived it.
Vaccine Boycott Grows in Northern Nigeria |
So there ya
go! Inactive ingredients, such as peanut oil in an adjuvant or vaccine
carrier, does not have to appear on the label of a vaccine.
|
Add This Entry To Your CureZone Favorites! Print this page
Email this page
Alert Webmaster
|